FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8123人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839800, encodeId=d62d1839800f4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准四价脑膜炎球菌疫苗MenQuadfi的生物制剂许可, objectType=article, longId=193026, objectId=8add1930261a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8add1930261a, replyNumber=0, likeNumber=64, createdTime=2020-09-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8add1930261a, moduleTitle=FDA批准四价脑膜炎球菌疫苗MenQuadfi的生物制剂许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8add1930261a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839845, encodeId=74d5183984590, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准血液癌口服药物——低甲基化制剂Inqovi, objectType=article, longId=197254, objectId=a8b119e2542e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b119e2542e, replyNumber=0, likeNumber=48, createdTime=2021-01-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b119e2542e, moduleTitle=FDA批准血液癌口服药物——低甲基化制剂Inqovi, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b119e2542e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839889, encodeId=fcc618398895c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）, objectType=article, longId=203274, objectId=cfcb2032e4c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfcb2032e4c1, replyNumber=0, likeNumber=59, createdTime=2021-03-24, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfcb2032e4c1, moduleTitle=FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfcb2032e4c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839887, encodeId=dee9183988e24, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=诺诚健华奥布替尼获美国FDA批准开展治疗多发性硬化症临床II期研究, objectType=article, longId=202938, objectId=6e7f20293886, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e7f20293886, replyNumber=0, likeNumber=60, createdTime=2021-03-13, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e7f20293886, moduleTitle=诺诚健华奥布替尼获美国FDA批准开展治疗多发性硬化症临床II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e7f20293886)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839898, encodeId=0f061839898a3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=2020年12月18日全球新冠肺炎（COVID-19）疫情简报，确诊超7520万，Moderna疫苗也被FDA批准上市, objectType=article, longId=204644, objectId=2780204644ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2780204644ec, replyNumber=0, likeNumber=55, createdTime=2021-06-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2780204644ec, moduleTitle=2020年12月18日全球新冠肺炎（COVID-19）疫情简报，确诊超7520万，Moderna疫苗也被FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2780204644ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839796, encodeId=fddb1839e9661, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准UroGen的丝裂霉素凝胶Jelmyto，治疗低级别尿路上皮癌, objectType=article, longId=192478, objectId=52191924e8ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52191924e8ba, replyNumber=0, likeNumber=73, createdTime=2020-11-15, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52191924e8ba, moduleTitle=FDA批准UroGen的丝裂霉素凝胶Jelmyto，治疗低级别尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52191924e8ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839828, encodeId=f6221839828aa, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab, objectType=article, longId=196063, objectId=e34d196063ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e34d196063ce, replyNumber=0, likeNumber=67, createdTime=2021-01-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e34d196063ce, moduleTitle=FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e34d196063ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839798, encodeId=650c1839e9823, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准胆管癌FGFR靶向药pemigatinib获批, objectType=article, longId=192611, objectId=3a2319261150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a2319261150, replyNumber=0, likeNumber=72, createdTime=2020-09-11, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a2319261150, moduleTitle=FDA批准胆管癌FGFR靶向药pemigatinib获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a2319261150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839811, encodeId=dcf918398112c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=达格列净获获FDA批准治疗心衰！“灵魂砍价药物”又一喜讯, objectType=article, longId=193711, objectId=7243193e11ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7243193e11ac, replyNumber=0, likeNumber=60, createdTime=2020-11-30, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7243193e11ac, moduleTitle=达格列净获获FDA批准治疗心衰！“灵魂砍价药物”又一喜讯, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7243193e11ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839799, encodeId=266f1839e9938, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准靶向Trop-2的ADC药物Trodelvy，治疗三阴性乳腺癌, objectType=article, longId=192955, objectId=c84119295539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84119295539, replyNumber=0, likeNumber=74, createdTime=2020-09-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84119295539, moduleTitle=FDA批准靶向Trop-2的ADC药物Trodelvy，治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84119295539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839814, encodeId=030c1839814e7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=194250, objectId=8f001942503c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f001942503c, replyNumber=0, likeNumber=70, createdTime=2020-12-12, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f001942503c, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f001942503c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839774, encodeId=16891839e7436, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准新一代抗CTLA-4抗体HBM4003治疗癌症的IND, objectType=article, longId=189090, objectId=bc2b1890908d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc2b1890908d, replyNumber=0, likeNumber=54, createdTime=2020-05-21, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc2b1890908d, moduleTitle=美国FDA批准新一代抗CTLA-4抗体HBM4003治疗癌症的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc2b1890908d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839802, encodeId=74bb183980269, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=绿谷制药的阿尔茨海默症新药GV-971，获得FDA批准在美国开展临床试验, objectType=article, longId=193134, objectId=3568193134a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3568193134a0, replyNumber=0, likeNumber=60, createdTime=2020-06-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3568193134a0, moduleTitle=绿谷制药的阿尔茨海默症新药GV-971，获得FDA批准在美国开展临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3568193134a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839782, encodeId=db0a1839e8251, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=吉利德的丙肝药物Epclusa在儿童感染患者中应答率超过90%，喜获FDA批准, objectType=article, longId=190494, objectId=01b81904941b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01b81904941b, replyNumber=0, likeNumber=66, createdTime=2020-12-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01b81904941b, moduleTitle=吉利德的丙肝药物Epclusa在儿童感染患者中应答率超过90%，喜获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01b81904941b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839827, encodeId=9213183982eed, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准PD-1单抗Keytruda的第二种基于生物标志物的肿瘤适应症, objectType=article, longId=196062, objectId=59a819606271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59a819606271, replyNumber=0, likeNumber=66, createdTime=2020-09-24, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59a819606271, moduleTitle=FDA批准PD-1单抗Keytruda的第二种基于生物标志物的肿瘤适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59a819606271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839767, encodeId=f5031839e674b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了Agile Therapeutics每周一次的避孕贴片Twirla, objectType=article, longId=188270, objectId=e6841882e006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6841882e006, replyNumber=0, likeNumber=51, createdTime=2020-12-30, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6841882e006, moduleTitle=FDA批准了Agile Therapeutics每周一次的避孕贴片Twirla, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6841882e006)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839894, encodeId=c84d1839894e0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Danyelza用于骨骼或骨髓复发或难治性神经母细胞瘤, objectType=article, longId=203851, objectId=77f320385182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77f320385182, replyNumber=0, likeNumber=75, createdTime=2020-12-14, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77f320385182, moduleTitle=FDA批准Danyelza用于骨骼或骨髓复发或难治性神经母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77f320385182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839768, encodeId=2f481839e6850, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准CMN-001治疗晚期转移性肾细胞癌的IND, objectType=article, longId=188492, objectId=cfd518849273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfd518849273, replyNumber=0, likeNumber=61, createdTime=2020-08-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfd518849273, moduleTitle=FDA批准CMN-001治疗晚期转移性肾细胞癌的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfd518849273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839881, encodeId=43ca18398812e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=未来可期！获得FDA批准的埃博拉治疗药物，银马泽伯来了！, objectType=article, longId=202205, objectId=61fc202205f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61fc202205f0, replyNumber=0, likeNumber=35, createdTime=2021-03-15, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61fc202205f0, moduleTitle=未来可期！获得FDA批准的埃博拉治疗药物，银马泽伯来了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61fc202205f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839829, encodeId=292918398296f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎, objectType=article, longId=196068, objectId=36e6196068e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36e6196068e4, replyNumber=0, likeNumber=72, createdTime=2020-06-30, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36e6196068e4, moduleTitle=FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36e6196068e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准四价脑膜炎球菌疫苗MenQuadfi的生物制剂许可

2020-09-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准血液癌口服药物——低甲基化制剂Inqovi

2021-01-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）

2021-03-24

bugit (审核中...)

前往app查看评论内容

#FDA批准#

诺诚健华奥布替尼获美国FDA批准开展治疗多发性硬化症临床II期研究

2021-03-13

bugit (审核中...)

前往app查看评论内容

#FDA批准#

2020年12月18日全球新冠肺炎（COVID-19）疫情简报，确诊超7520万，Moderna疫苗也被FDA批准上市

2021-06-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准UroGen的丝裂霉素凝胶Jelmyto，治疗低级别尿路上皮癌

2020-11-15

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab

2021-01-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准胆管癌FGFR靶向药pemigatinib获批

2020-09-11

bugit (审核中...)

前往app查看评论内容

#FDA批准#

达格列净获获FDA批准治疗心衰！“灵魂砍价药物”又一喜讯

2020-11-30

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准靶向Trop-2的ADC药物Trodelvy，治疗三阴性乳腺癌

2020-09-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2020-12-12

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准新一代抗CTLA-4抗体HBM4003治疗癌症的IND

2020-05-21

bugit (审核中...)

前往app查看评论内容

#FDA批准#

绿谷制药的阿尔茨海默症新药GV-971，获得FDA批准在美国开展临床试验

2020-06-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

吉利德的丙肝药物Epclusa在儿童感染患者中应答率超过90%，喜获FDA批准

2020-12-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准PD-1单抗Keytruda的第二种基于生物标志物的肿瘤适应症

2020-09-24

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了Agile Therapeutics每周一次的避孕贴片Twirla

2020-12-30

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Danyelza用于骨骼或骨髓复发或难治性神经母细胞瘤

2020-12-14

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准CMN-001治疗晚期转移性肾细胞癌的IND

2020-08-01

bugit (审核中...)

前往app查看评论内容

#FDA批准#

未来可期！获得FDA批准的埃博拉治疗药物，银马泽伯来了！

2021-03-15

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎

2020-06-30

科室
- - 订阅+
  - 更多科室
工具
服务